Zangemeister-Wittke Group

Uwe Zangemeister‐Wittke obtained his PhD in the field of cellular immunology and tumorimmunology from the Technical University of Stuttgart and the German Cancer Research Center in Heidelberg. After several years of training at the Department of Oncology and head of experimental oncology research at the University of Zürich he currently works as a group leader at the Institute of Pharmacology of Bern University. In addition to investigating the role of sphingolipid signaling in malignant progression together with the team of A. Huwiler, his major research focus is on engineering advanced chemistry nanomedicines, alternative non‐IgG binding proteins and cytotoxic drug conjugates for tumor targeting. This work is done in close collaboration with the team of A. Plückthun at the Institute of Biochemistry of Zürich University. His teaching responsibilities include lectures in pharmacokinetics, cardiovascular pharmacology, tumor pharmacology and targeted cancer therapy.


Jump to: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006


Brandl, Fabian; Busslinger, Sarah; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2020). Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. Journal of controlled release, 327, pp. 186-197. Elsevier 10.1016/j.jconrel.2020.08.004

Schwalm, Stephanie; Erhardt, Martin; Römer, Isolde; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe; Huwiler, Andrea (2020). Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt. International journal of molecular sciences, 21(4) Molecular Diversity Preservation International MDPI 10.3390/ijms21041396


Brandl, Fabian; Merten, Hannes; Zimmermann, Martina; Béhé, Martin; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. Journal of controlled release, 307, pp. 379-392. Elsevier 10.1016/j.jconrel.2019.06.030

Lorenzer, Cornelia; Streußnig, Sonja; Tot, Emilia; Winkler, Anna-Maria; Merten, Hannes; Brandl, Fabian; Sayers, Edward J; Watson, Peter; Jones, Arwyn T; Zangemeister-Wittke, Uwe; Plückthun, Andreas; Winkler, Johannes (2019). Targeted delivery and endosomal cellular uptake of DARPin-siRNA bioconjugates: Influence of linker stability on gene silencing. European journal of pharmaceutics and biopharmaceutics, 141, pp. 37-50. Elsevier 10.1016/j.ejpb.2019.05.015

Merten, Hannes; Schaefer, Jonas V; Brandl, Fabian; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2019). Facile Site-Specific Multiconjugation Strategies in Recombinant Proteins Produced in Bacteria. Methods in molecular biology, 2033, pp. 253-273. Springer 10.1007/978-1-4939-9654-4_17


Blanchard, Olivier; Stepanovska, Bisera; Starck, Manuel Thierry; Erhardt, Martin; Römer, Isolde; Meyer Zu Heringdorf, Dagmar; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe; Huwiler, Andrea (2018). Downregulation of the S1P Transporter Spinster Homology Protein 2 (Spns2) Exerts an Anti-Fibrotic and Anti-Inflammatory Effect in Human Renal Proximal Tubular Epithelial Cells. International journal of molecular sciences, 19(5) Molecular Diversity Preservation International MDPI 10.3390/ijms19051498

Huwiler, Andrea; Zangemeister-Wittke, Uwe (2018). The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. Pharmacology & therapeutics, 185, pp. 34-49. Elsevier 10.1016/j.pharmthera.2017.11.001


Graumann, Rebecca; Di Capua, Gabriella A; Oyarzún, Juan E; Vásquez, Marcos A; Liao, Christine; Brañes, Jorge A; Roa, Iván; Casanello, Paola; Corvalán, Alejandro H; Owen, Gareth I; Delgado, Iris; Zangemeister-Wittke, Uwe; Ziegler, Annemarie (2017). Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer. PLoS ONE, 12(5), e0177244. Public Library of Science 10.1371/journal.pone.0177244


Filipenko, Iuliia; Schwalm, Stephanie; Reali, Luca; Pfeilschifter, Josef; Fabbro, Doriano; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2016). Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation. Biochimica et biophysica acta (BBA) - molecular and cell biology of lipids, 1861(11), pp. 1840-1851. Elsevier 10.1016/j.bbalip.2016.09.005

Simon, Hans-Uwe; Zangemeister-Wittke, Uwe (2016). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer. Heidelberg: Springer

Filipenko, Iuliia; Huwiler, Andrea (2016). The role of the S1P3 receptor in inflammation-associated proliferative disorders (Submitted). (Dissertation, Graduate School for Cellular and Biomedical Sciences, University of Bern, Faculty of Medicine)


Merten, Hannes; Brandl, Fabian; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2015). Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins. Bioconjugate chemistry, 26(11), pp. 2176-2185. American Chemical Society 10.1021/acs.bioconjchem.5b00260

Schwalm, Stephanie; Maneva Timcheva, Tankica; Filipenko, Iuliia; Ebadi, Mahsa; Hofmann, Lotte P; Zangemeister-Wittke, Uwe; Pfeilschifter, Josef; Huwiler, Andrea (2015). Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts. Biological chemistry, 396(6-7), pp. 813-825. De Gruyter 10.1515/hsz-2014-0289


Pastukhov, Oleksandr; Schalm, Stephanie; Zangemeister-Wittke, Uwe; Fabbro, Doriano; Bornancin, Frederic; Japtok, Lukasz; Kleuser, Burkhrad; Pfeilschifter, Josef; Huwiler, Andrea (2014). The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death. British journal of pharmacology, 171(24), pp. 5829-5844. Wiley-Blackwell 10.1111/bph.12886

Stefan, Nikolas; Zimmermann, Martina; Simon, Manuel; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2014). Novel Prodrug-Like Fusion Toxin with Protease-Sensitive Bioorthogonal PEGylation for Tumor Targeting. Bioconjugate chemistry, 25(12), pp. 2144-2156. American Chemical Society 10.1021/bc500468s

Thangaiyan, Rabi; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2014). AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells. Molecular carcinogenesis, 53(7), pp. 578-588. Wiley 10.1002/mc.22012

Simon, Manuel; Stefan, Nikolas; Borsig, Lubor; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2014). Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation. Molecular cancer therapeutics, 2(13), pp. 375-385. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0523

Pastukhov, Oleksandr; Schalm, Stephanie; Römer, Isolde; Pfeilschifter, Josef; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2014). Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts. Cellular physiology and biochemistry, 34(1), pp. 119-133. Karger 10.1159/000362989


Wojtalla, Anna; Fischer, Barbara; Kotelevets, Nataliya; Mauri, Francesco A; Sobek, Jens; Rehrauer, Hubert; Wotzkow, Carlos; Tschan, Mario P; Seckl, Michael J; Zangemeister-Wittke, Uwe; Arcaro, Alexandre (2013). Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clinical cancer research, 19(1), pp. 96-105. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-1138

Simon, Manuel; Frey, Raphael; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2013). Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. Bioconjugate chemistry, 24(11), pp. 1955-1986. American Chemical Society 10.1021/bc4004102

Simon, Manuel; Stefan, Nikolas; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2013). Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert opinion on drug delivery, 10(4), pp. 451-468. Taylor & Francis 10.1517/17425247.2013.759938


Kotelevets, Nataliya; Fabbro, Doriano; Huwiler, Andrea; Zangemeister-Wittke, Uwe (2012). Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis. PLoS ONE, 7(6), e39209. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0039209

Heine, Markus; Freund, Barbara; Nielsen, Peter; Jung, Caroline; Reimer, Rudolph; Hohenberg, Heinrich; Zangemeister-Wittke, Uwe; Wester, Hans-Juergen; Lüers, Georg H; Schumacher, Udo (2012). High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS ONE, 7(5), e36258. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0036258

Simon, Manuel; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2012). Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconjugate chemistry, 23(2), pp. 279-86. Washington, D.C.: American Chemical Society 10.1021/bc200591x

Zangemeister-Wittke, Uwe; Simon, Hans-Uwe (2012). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer (pp. 2437-2440). Heidelberg: Springer-Verlage 10.1007/978-3-642-16483-5


Patricia, Martin-Killias; Stefan, Nikolas; Rothschild, Sacha; Plückthun, Andreas; Zangemeister-Wittke, Uwe (2011). A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clinical cancer research, 17(1), pp. 100-10. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-10-1303

Huwiler, Andrea; Bourquin, Florence; Kotelevets, Nataliya; Pastukhov, Oleksandr; Capitani, Guido; Grütter, Markus G; Zangemeister-Wittke, Uwe (2011). A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders. PLoS ONE, 6(8), e22436. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0022436

Huwiler, Andrea; Kotelevets, Nataliya; Xin, Cuiyan; Pastukhov, Oleksandr; Pfeilschifter, Josef; Zangemeister-Wittke, Uwe (2011). Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. British journal of pharmacology, 162(2), pp. 532-43. Oxford: Wiley-Blackwell 10.1111/j.1476-5381.2010.01053.x

Stefan, Nikolas; Martin-Killias, Patricia; Wyss-Stoeckle, Sascha; Honegger, Annemarie; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2011). DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. Journal of molecular biology, 413(4), pp. 826-43. Amsterdam: Elsevier 10.1016/j.jmb.2011.09.016

Lange, Annika; Gustke, Heike; Glassmeier, Günter; Heine, Markus; Zangemeister-Wittke, Uwe; Schwarz, Jürgen R; Schumacher, Udo; Lange, Tobias (2011). Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung cancer, 74(2), pp. 178-87. Amsterdam: Elsevier 10.1016/j.lungcan.2011.03.017


Zangemeister-Wittke, Uwe; Simon, Hans-Uwe (2009). Myelosuppression. In: Schwab, Manfred (ed.) Encyclopedia of Cancer, 2nd Edition (pp. 2008-2010). Heidelberg: Springer Verlag 10.1007/978-3-540-47648-1_3940


Belyanskaya, Larisa L; Ziogas, Algirdas; Hopkins-Donaldson, Sally; Kurtz, Stefanie; Simon, Hans-Uwe; Stahel, Rolf; Zangemeister-Wittke, Uwe (2008). TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8. Lung cancer, 60(3), pp. 355-65. Amsterdam: Elsevier 10.1016/j.lungcan.2007.11.005


Hussain, Sajid; Plückthun, Andreas; Allen, Theresa M; Zangemeister-Wittke, Uwe (2007). Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Molecular cancer therapeutics, 6(11), pp. 3019-27. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1535-7163.MCT-07-0615

Giorgini, Simona; Trisciuoglio, Daniela; Gabellini, Chiara; Desideri, Marianna; Castellini, Laura; Colarossi, Cristina; Zangemeister-Wittke, Uwe; Zupi, Gabriella; Del Bufalo, Donatella (2007). Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Molecular cancer research, 5(8), pp. 761-71. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1541-7786.MCR-07-0088

Huwiler, Andrea; Zangemeister-Wittke, Uwe (2007). Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Critical reviews in oncology, hematology, 63(2), pp. 150-9. Boca Raton, Fla.: Elsevier 10.1016/j.critrevonc.2007.04.010

Zangemeister-Wittke, Uwe (2007). Krebsbehandlung mit Antisensemolekülen. Onkologe, 13(2007), pp. 256-262. Heidelberg: Springer-Medizin-Verlag

Zangemeister-Wittke, Uwe (2007). Antisense molecules for targeted cancer therapy. Onkologe, 13(3), pp. 256-262. Springer-Medizin-Verlag 10.1007/s00761-006-1170-z


Zangemeister-Wittke, Uwe; Huwiler, Andrea (2006). Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer. Cancer biology & therapy, 5(10), pp. 1355-1356. Georgetown, Tex.: Landes Bioscience 10.4161/cbt.5.10.3488

Hussain, Sajid; Plückthun, Andreas; Allen, Theresa M; Zangemeister-Wittke, Uwe (2006). Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Molecular cancer therapeutics, 5(12), pp. 3170-80. Philadelphia, Pa.: American Association for Cancer Research AACR 10.1158/1535-7163.MCT-06-0412

Mousavi-Shafaei, Parisa; Ziaee, Abed-Ali; Azizi, Ebrahim; Zangemeister-Wittke, Uwe (2006). Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin. Anti-cancer drugs, 17(9), pp. 1031-9. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.cad.0000231474.77159.e3

Kubetzko, Susanne; Balic, Ela; Waibel, Robert; Zangemeister-Wittke, Uwe; Plückthun, Andreas (2006). PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. Journal of biological chemistry, 281(46), pp. 35186-201. Bethesda, Md.: American Society for Biochemistry and Molecular Biology 10.1074/jbc.M604127200

Hopkins-Donaldson, Sally; Belyanskaya, Larisa L; Simões-Wüst, Ana Paula; Sigrist, Brigitte; Kurtz, Stefanie; Zangemeister-Wittke, Uwe; Stahel, Rolf (2006). p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia, 8(7), pp. 551-9. New York, N.Y.: Nature America 10.1593/neo.06148

Wacheck, V; Zangemeister-Wittke, Uwe (2006). Antisense molecules for targeted cancer therapy. Critical reviews in oncology, hematology, 59(1), pp. 65-73. Boca Raton, Fla.: Elsevier 10.1016/j.critrevonc.2005.10.004

Yamanaka, Kazuki; Rocchi, Palma; Miyake, Hideaki; Fazli, Ladan; So, Alan; Zangemeister-Wittke, Uwe; Gleave, Martin E (2006). Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU international, 97(6), pp. 1300-8. Oxford: Blackwell Science 10.1111/j.1464-410X.2006.06147.x